A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity
Public ClinicalTrials.gov record NCT04707313. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06882961 ADMINISTRATION IN ADULTS WITH OBESITY
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-06882961) for the potential treatment of obesity. The study will compare the experiences of participants taking the study medicine (PF-06882961) to those of participants who take placebo (a look- alike substance that contains no active study medicine). The aim is to measure the body's response to the study medicine, including any changes in participants' body weight, waist and hip measurements, how well they tolerate the study medicine, and to measure levels of the study medicine in participants' blood. This study is seeking participants who have obesity, who do not have diabetes and who have had a stable body weight and not participated in a formal weight loss program in the 90 days before the study. The study medicine or placebo will be taken as tablets by mouth 2 times a day (1 time in the morning and 1 time in the evening). There are 3 groups of participants (called cohorts) in this study. For participants in Cohorts 1 and 2, total study participation will be about 9 months, with 15 planned study visits (14 visits to the study clinic and 1 telephone call). For participants in Cohort 3, total study participation will be about 10 months, with 21 planned study visits (12 visits to the study clinic and 9 telephone calls).
Study identification
- NCT ID
- NCT04707313
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 628 participants
Conditions and interventions
Conditions
Interventions
- Placebo (Cohorts 1 and 2) Drug
- PF-06882961 (Cohorts 1 and 2) Drug
- Placebo (Cohort 3) Drug
- PF-06882961 (Cohort 3) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 29, 2021 (Actual)
- Primary completion
- Sep 13, 2023 (Actual)
- Completion
- Oct 11, 2023 (Actual)
- Last update posted
- Nov 5, 2024
2021 – 2023
United States locations
- U.S. sites
- 27
- U.S. states
- 14
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pinnacle Research Group, LLC | Anniston | Alabama | 36207 | — |
| Anaheim Clinical Trials, LLC | Anaheim | California | 92801 | — |
| Velocity Clinical Research - Westlake | Los Angeles | California | 90057 | — |
| Alliance for Multispecialty Research, LLC | Coral Gables | Florida | 33134 | — |
| Optimus U Corporation | Miami | Florida | 33125 | — |
| Clinical Neuroscience Solutions, Inc. | Orlando | Florida | 32801 | — |
| ForCare Clinical Research | Tampa | Florida | 33613 | — |
| Clinical Investigation Specialists | Gurnee | Illinois | 60031 | — |
| MediSphere Medical Research Center, LLC | Evansville | Indiana | 47714 | — |
| Velocity Clinical Research, Valparaiso | Valparaiso | Indiana | 46383 | — |
| Cotton O'Neil Clinical Research Center | Topeka | Kansas | 66606 | — |
| L-MARC Research Center | Louisville | Kentucky | 40213 | — |
| ActivMed Practices & Research, LLC | Methuen | Massachusetts | 01844 | — |
| Velocity Clinical Research, Omaha | Omaha | Nebraska | 68134 | — |
| PMG Research of Hickory, LLC | Hickory | North Carolina | 28601 | — |
| PMG Research of Raleigh, LLC | Raleigh | North Carolina | 27609 | — |
| PMG Research of Salisbury, LLC | Salisbury | North Carolina | 28144 | — |
| Accellacare - Wilmington | Wilmington | North Carolina | 28401 | — |
| Lillestol Research LLC | Fargo | North Dakota | 58104 | — |
| Velocity Clinical Research, Inc. | Cleveland | Ohio | 44122 | — |
| Clinical Trials of South Carolina | Moncks Corner | South Carolina | 29461 | — |
| Coastal Carolina Research Center | North Charleston | South Carolina | 29405 | — |
| Palmetto Clinical Research | Summerville | South Carolina | 29485 | — |
| Palmetto Primary Care Physicians (Sub-I physicals only) | Summerville | South Carolina | 29485 | — |
| Internal Medicine and Pediatric Associates of Bristol, PC | Bristol | Tennessee | 37620 | — |
| PMG Research, Inc. d/b/a PMG Research of Knoxville | Knoxville | Tennessee | 37938 | — |
| Clinical Neuroscience Solutions, Inc. | Memphis | Tennessee | 38119 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04707313, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 5, 2024 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04707313 live on ClinicalTrials.gov.